Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penn Microbiome Therapy for Multidrug-Resistant Organisms
NCT05632315Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Cell Therapies, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in bacterial infection, Enterobacteriaceae infection, Pseudomonas aeruginosa infection and 2 more (24 arms), sponsored by University of Pennsylvania. Primary endpoints: Proportion of subjects with resolution of index MDRO colonization of the gut, Frequency of solicited adverse events and 3 more. Started Aug 2024; status: completed.
02
Conditions
bacterial infectionEnterobacteriaceae infectionPseudomonas aeruginosa infectionEnterococcus infectionStaphylococcus aureus infection
Beyond the preview
Go deeper on NCT05632315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632315.